Company intelligence / Profile preview

Transgenomic

Omaha, Nebraska, United Statessec.gov ↗

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Transgenomic was a molecular diagnostics company specializing in proprietary technologies for detecting genetic mutations relevant to cancer diagnosis and therapy selection. Its platforms included ICE COLD-PCR for non-invasive tumor profiling using circulating DNA and the WAVE system for high-sensitivity mutation analysis. The company offered commercialized tests and partnered with academic centers and pharma companies before merging with Precipio Diagnostics in late 2017.

Therapeutic areas: Oncology
Modalities: Diagnostic testMutation detection technologySmall moleculeNucleic acid-based assay
Industry: Molecular Diagnostics

Partnerships

Montefiore Medical Center licensing agreementdistribution partners for ICP platformpharma collaborations on biomarker assays

Beyond the preview

Go deeper on Transgenomic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transgenomic.

Explore the full profile